Avita Medical Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- AVITA Medical, Inc. (NASDAQ: RCEL; ASX: AVH) is a commercial-stage regenerative medicine company focused on therapeutic acute wound care solutions that accelerate skin healing and patient recovery. Founded in 1993 as Clinical Cell Culture in Perth, Western Australia, and restructured as AVITA Medical in 2008 with current headquarters in Valencia, California, the company develops and commercializes autologous cell-based technologies including its lead product, the RECELL System, an FDA-approved device for treating thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions; PermeaDerm, a biosynthetic wound matrix; and Cohealyx, a branded collagen-based dermal matrix, all marketed primarily in the United States with distribution and operations extending to Japan, the European Union, Australia, the United Kingdom, and New Zealand. The RECELL System utilizes a patient's own skin sample processed at point-of-care to produce Spray-On Skin Cells via single-use RECELL GO cartridges and multi-use processing devices, enabling reduced donor site requirements and improved outcomes for burns, trauma, surgical wounds, and vitiligo in hospitals, burn centers, dermatology clinics, and plastic surgery settings. Recent developments include an exclusive multi-year development and distribution agreement with Regenity Biosciences announced in July 2024 for a novel collagen-based dermal matrix (branded Cohealyx), anticipated to receive FDA 510(k) clearance in late 2024 for U.S. commercialization alongside potential expansion to the EU, Australia, and Japan; an exclusive distribution partnership with Revolution Surgical Pty Ltd in November 2024 to reintroduce RECELL into Australia and New Zealand; FDA approval expansions for RECELL in vitiligo and soft tissue reconstruction boosting 2025 commercial revenues to $18.4 million in Q2 (up 21% year-over-year); and a name change from AVITA Therapeutics, Inc. to AVITA Medical, Inc. to better reflect its wound care focus.
Company News
AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference
All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy
Avita Medical Inc. (RCEL) is a Great Momentum Stock: Should You Buy?
AVITA Medical: Favorable Reimbursements For Skin Wound Care
Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes
Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%
Avita Medical Targets Q4 2025 Cash Flow Breakeven as Revenue Growth Builds
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical Announces Participation at Canaccord Genuity Growth Conference
Avita Medical Q2 Earnings Call Highlights
AVITA Medical, Inc. (RCEL) Q2 2026 Earnings Call Transcript
AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven
AVITA Medical to Announce Second Quarter 2026 Financial Results
Avita Medical (RCEL) Upgraded to Buy: Here's Why
AVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual Meeting
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Prepared Remarks Transcript
AVITA Medical, Inc. (RCEL) Discusses Business Progress, Operational Changes and Sequential Revenue Growth Transcript